Dual Action of miR-125b As a Tumor Suppressor and OncomiR-22 Promotes Prostate Cancer Tumorigenesis by Budd, William T. et al.
Virginia Commonwealth University
VCU Scholars Compass
Biochemistry and Molecular Biology Publications Dept. of Biochemistry and Molecular Biology
2015
Dual Action of miR-125b As a Tumor Suppressor
and OncomiR-22 Promotes Prostate Cancer
Tumorigenesis
William T. Budd
Virginia Commonwealth University, buddwt@vcu.edu
Sarah J. Seashols-Williams
Virginia Commonwealth University, sseashols@vcu.edu
Gene C. Clark
Virginia Commonwealth University, Clarkgc@vcu.edu
See next page for additional authors
Follow this and additional works at: http://scholarscompass.vcu.edu/bioc_pubs
Part of the Medicine and Health Sciences Commons
Copyright © 2015 Budd et al. This is an open access article distributed under the terms of the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original
author and source are credited
This Article is brought to you for free and open access by the Dept. of Biochemistry and Molecular Biology at VCU Scholars Compass. It has been
accepted for inclusion in Biochemistry and Molecular Biology Publications by an authorized administrator of VCU Scholars Compass. For more
information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/bioc_pubs/23
Authors
William T. Budd, Sarah J. Seashols-Williams, Gene C. Clark, Danielle Weaver, Valerie Calvert, Emanuel
Petricoin, Ema A. Dragoescu, Katherine O'Hanlon, and Zendra E. Zehner
This article is available at VCU Scholars Compass: http://scholarscompass.vcu.edu/bioc_pubs/23
RESEARCH ARTICLE
Dual Action of miR-125b As a Tumor
Suppressor and OncomiR-22 Promotes
Prostate Cancer Tumorigenesis
William T. Budd1¤, Sarah J. Seashols-Williams1,2, Gene C. Clark1, Danielle Weaver3,
Valerie Calvert4, Emanuel Petricoin4, Ema A. Dragoescu5, Katherine O’Hanlon6, Zendra
E. Zehner1*
1 Department of Biochemistry and Molecular Biology, Massey Cancer Center, Virginia Commonwealth
University, Richmond, Virginia, United States of America, 2 Department of Forensic Science, Virginia
Commonwealth University, Richmond, Virginia, United States of America, 3 Center for the Study of
Biological Complexity, Virginia Commonwealth University, Richmond, Virginia, United States of America,
4 Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia,
United States of America, 5 Department of Pathology, VCUMedical Center, Virginia Commonwealth
University, Richmond, Virginia, United States of America, 6 American International Biotechnology,
Richmond, Virginia, United States of America
¤ Current address: American International Biotechnology, Richmond, Virginia, United States of America
* zendra.zehner@vcuhealth.org
Abstract
MicroRNAs (miRs) are a novel class of small RNA molecules, the dysregulation of which
can contribute to cancer. A combinatorial approach was used to identify miRs that promote
prostate cancer progression in a unique set of prostate cancer cell lines, which originate
from the parental p69 cell line and extend to a highly tumorigenic/metastatic M12 subline.
Together, these cell lines are thought to mimic prostate cancer progression in vivo. Previous
network analysis and miR arrays suggested that the loss of hsa-miR-125b together with the
overexpression of hsa-miR-22 could contribute to prostate tumorigenesis. The dysregula-
tion of these two miRs was confirmed in human prostate tumor samples as compared to
adjacent benign glandular epithelium collected through laser capture microdissection from
radical prostatectomies. In fact, alterations in hsa-miR-125b expression appeared to be an
early event in tumorigenesis. Reverse phase microarray proteomic analysis revealed
ErbB2/3 and downstreammembers of the PI3K/AKT and MAPK/ERK pathways as well as
PTEN to be protein targets differentially expressed in the M12 tumor cell compared to its
parental p69 cell. Relevant luciferase+3’-UTR expression studies confirmed a direct interac-
tion between hsa-miR-125b and ErbB2 and between hsa-miR-22 and PTEN. Restoration of
hsa-miR-125b or inhibition of hsa-miR-22 expression via an antagomiR resulted in an alter-
ation of M12 tumor cell behavior in vitro. Thus, the dual action of hsa-miR-125b as a tumor
suppressor and hsa-miR-22 as an oncomiR contributed to prostate tumorigenesis by modu-
lations in PI3K/AKT and MAPK/ERK signaling pathways, key pathways known to influence
prostate cancer progression.
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Introduction
Transformation, growth and extravasation of cancer cells results from a variety of genetic and
epigenetic modifications. In the past decade, there has been a growing body of literature report-
ing that aberrant expression of microRNAs (miRs) contributes to the development of several
human cancers [1–8]. miRs are an important class of non-coding RNAs that affect post-tran-
scriptional protein levels and, in the presence of external cues and environmental stressors,
have the ability to induce rapid changes in the proteome allowing the cell to respond in a more
precise and energy efficient manner [2–5]. Numerous cellular processes are affected by miRs,
including differentiation, growth/ hypertrophy, cell cycle control and apoptosis [5,6].
Dysregulated miRs have been shown to contribute to oncogenesis by the loss of tumor sup-
pressing miRs or increased expression of oncomiRs [1,9,10]. Either loss of tumor suppressors
or increased expression of oncomiRs ultimately results in increased cell growth, proliferation,
invasiveness or metastasis. Aberrant expression of even a single miR has the potential to influ-
ence a large number of cellular processes, as each miR can affect hundreds of downstream pro-
teins, which preferentially regulate important key cell signaling nodes and transcription factors
[11]. Networks analysis shows that targets of miRs have a significantly higher node degree than
randomly chosen genes [11,12]. Perturbation of these highly interconnected molecules impacts
cell health leading to disease.
Therefore, it seems necessary to integrate multiple sources of biological information to
understand the perturbations underlying a given pathology from a systems level. High
throughput technologies such as DNA microarray, genome sequencing, reverse phase proteo-
mics, and qRT-PCR profiling allow for the simultaneous acquisition of thousands of data
points. The intersection of multiple data sources increases the likelihood of identifying key
pathways involved in cancer initiation, progression and metastasis. This work describes a
unique combinatorial approach to understand the impact of miR dysregulation upon prostate
cancer progression. Although miRs have been observed to be associated with prostate cancer,
there is not a clear consensus on specific miRs that contribute to oncogenesis [7,8].
A novel isogenic prostate cancer cell line progression model was used as it is thought to
closely mimic tumor progression as it occurs in vivo [13,14,15]. Integration of miR quantifica-
tion profiles and proteomic data has the potential to increase the success of identifying novel
miRs affecting tumorigenesis. Therefore, the data generated from miR arrays, Reverse Phase
Microarray (RPPA) proteomics, along with information from a previous networks analysis was
used to rank dysregulated miRs in our prostate cancer progression model [12,16–18]. Putative
dysregulated miRs were further verified in RNA isolated from patients’ radical prostatectomy
tumor samples using laser capture microdissection [LCM] [19,20]. Several dysregulated miRs
that potentially drive prostate cancer progression were identified [18,21]. Of these miRs, the
importance of hsa-miR-125b (miR-125b) and hsa-miR-22 (miR-22) to tumorigenesis was fur-
ther confirmed by in vitro experiments. miR-125b and miR-22 may be useful as relevant bio-
markers to identify and stage prostate cancer.
Materials and Methods
Derivation of Prostate Cell Lines and Cell Culture
p69, M2182, and M12 cells were a gift from Dr. Joy Ware, Virginia Commonwealth University,
Richmond VA, and authenticated using STR analysis [13,14]. These cell lines were derived by
immortalization of a non-neoplastic prostate epithelium with SV40 large T antigen [13]. The
parental (P69) cell line is poorly tumorigenic, and non-metastatic with a lower modal chromo-
some number than most other prostate cancer cell lines typically isolated from metastatic sites
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(LNCap, DU145, and PC3). An in vivo selection process was used to create cells with increased
tumorigenicity and metastatic potential. After three rounds of subcutaneous injections into
male athymic nude mice, a highly tumorigenic and metastatic variant (M12) was isolated,
which routinely metastasizes upon intra-prostatic injection [14]. The M2182 cell line was
derived after two rounds of in vivo selection and therefore represents an intermediate pheno-
type that is less tumorigenic than the M12 cells and is non-metastatic. Cells were kept in cul-
ture at 37°C for less than two months in RPMI1640 media with L-glutamine (Gibco),
supplemented with 5% fetal bovine serum, 0.05 mg/ml gentamycin, 5μg/ml insulin, 5 μg/ml
transferrin, and 5 μg/ml of selenium (ITS from Collaborative Research Bedford, MA)
[13,14,19]. M12 cells stably transformed with a pSIREN plasmid vector (Clontech) expressing
miR-125b (M12+miR-125b) were maintained with puromycin (100 ng/ml) [19,22]. M12 cells
stably transformed with a miARREST™miR22-3p inhibitor (M12+miR-22i) expression plas-
mid (pEZX-AM03) from GeneCopoeia (HmiR-AN0332-AM03) were maintained with hygro-
mycin (200 μg/ml). Following trypsinization (0.25% in EDTA), cells were pelleted, washed
with PBS, flash frozen in liquid nitrogen, and stored at -80°C until used.
Cell Pellet RNA Extraction
Total RNA was extracted from frozen cell pellets using the miRVana™miR isolation method
(Ambion-Life Technologies) per manufacturer’s instructions. After isolation, RNA concentra-
tion was estimated using a Biorad1 Smart Spec™3000 spectrophotometer, diluted to a concen-
tration of 100 ng/ml and stored at -80°C.
Cell Pellet DNA Extraction
DNA was extracted from frozen cell pellets using the QIAamp DNA mini kit from Qiagen
(Cat. No. 51304) following manufacturer’s instructions. Following extraction DNA concentra-
tion was measured as above.
Onco Library and Sequencing method
DNA libraries were generated from the cell lines using the Ion AmpliSeq™ Library Kit 2.0 and
the Ion AmpliSeq™ Cancer Hotspot Panel v2 (Cat. No. 4480441 and 4475346). The Cancer
Hotspot Panel is a single amplicon pool that amplifies 207 amplicons covering over 2,800 COS-
MIC mutations from 50 known oncogenes and tumor suppressor genes. Each sample was pre-
pared using 10 ng of input DNA according to the Ion AmpliSeq™ Library Preparation protocol
(Publication Part Number MAN0006735 Revision A.0). Ion Xpress™ Barcode Adapters 1–16
Kit (Cat. No. 4471250) were utilized for individual sample barcoding and adaptor ligation.
Agencourt AMPure XP magnetic beads (Cat. No. A63882, Beckman) were utilized as indicated
in the Ion AmpliSeq™ Library Preparation User Guide. Sample libraries were quantitated using
the Qubit 2.0 Fluorometer and the High Sensitivity dsDNA Assay Kit (Cat. No. Q32851) and
normalized to a concentration of 100 pM. Emulsion PCR was performed on the Ion One-
Touch™ 2 Instrument (Cat. No. 4474778) as indicated in Ion PGM™ Template OT2 200 Kit
(Publication Number MAN0007220. Revision 5.0) using the Ion PGM™ Template OT2 200 Kit
(Cat. No. 4480974). Normalized 100 pM sample libraries were pooled and combined with OT2
kit reagents and Ion Sphere Particles (ISPs). The reaction was run on the OT2 using the 200 bp
protocol. Samples were then processed for enrichment on the Ion OneTouch™ ES. Enrichment
of ISPs was achieved using the Ion PGM™ Template OT2 200 Kit (Cat. No. 4480974) and
DynaBeads MyOne streptavidin C1 beads (Cat. No. 65001 Life Technologies) according to the
manufacturer's protocols (Ion PGM™ Template OT2 200 Kit User Guide). The streptavidin C1
beads bind specifically to enriched ISPs, allowing all others to be washed away, followed by
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elution with a sodium hydroxide and tween melt solution. The Ion Torrent Personal Genome
Machine (PGM) was initialized using the Ion PGM™ Sequencing 200 Kit v2 according to man-
ufacturer’s recommendations (Ion PGM™ Sequencing 200 Kit v2: Publication Number
MAN0007273 Revision 3.0). Control beads were spiked into the enriched bead sample,
sequencing primers were annealed to the ISPs and polymerase added. ISPs were sequenced uti-
lizing an Ion Torrent Ion 318™ Chip. The Ion Torrent PGM was run according to Ion Torrent
200 Kit v2 specifications utilizing 500 nucleotide flows, followed by alignment to the HG19 ref-
erence and analyzed by the Ion Torrent Variant Caller plugin.
TaqMan1 based miR assay
Verification of mature miR expression was confirmed using TaqMan1miR methodology (Life
Technologies, Grand Island, NY). cDNA was synthesized in a 25 μl reaction volume from total
RNA (20 ng) using the TaqMan1MicroRNA Reverse Transcription kit. Reactions were incu-
bated at 16°C for 30 min, 42°C for 30 min, and inactivated at 85°C for 5 min. Each cDNA was
analyzed in triplicate by quantitative PCR (qRT-PCR) using the sequence specific primers hsa-
miR-125b-1 (ID 000449), hsa-miR-22-3p (ID 000398) or RNU48 (ID 001006) in an Applied
Biosystems 7300 real-time PCR instrument (Life Technologies). Each individual assay was per-
formed in a 20 μl reaction volume with 1.33 μl of cDNA, 1.0 μl specific miR assay, 10 μl Taq-
Man™ Universal PCRMaster Mix II with no AmpErase UNG and 7.67 μl of nuclease free
water. Reactions were incubated at 50°C for 2 min, followed by 10 min at 95°C and 40 cycles
with denaturation for 15 sec at 98°C, and annealing/extension for 60 sec at 60°C. Data was ana-
lyzed using SDS software v1.3.1 (Life Technologies). Threshold and baseline settings were set
according to protocol recommendations, with baseline correction between cycles 3 and 12 and
an automatic threshold.
Statistical Analysis of qRT-PCR Data
Relative quantities of miR levels were determined using the 2-ΔΔCT method of Livak et al after
normalization with RNU48 as a standard reference [23]. All samples were performed in tripli-
cate and the average cycle threshold (CT) value was determined from CT values in the range of
25 to 35. The average CT was normalized by subtracting the average CT of RNU48 (ΔCT). All
samples were compared to the parental P69 cell line by subtracting the experimental ΔCT from
the ΔCT value of the p69 cell line as the calibrator. Data are presented as the mean ± standard
deviation of 3 independent experiments. Statistical analyses were conducted in the Microsoft1
Excel software platform, using an independent Student's t-test, assuming equal variance
between the two groups. Statistical significance was defined as p≦0.05.
Laser Capture Microdissection (LCM)
Tumor and benign prostate tissues were obtained from radical prostatectomy samples, after
approval from Virginia Commonwealth University (VCU), Office of Research and Innovation,
Institutional Review Board (IRB), Panel A. Four samples were frozen tissue from VCU’s Tissue
and Data Acquisition and Analysis Core (TDAAC at http://www.pathology.vcu.edu/research/
TDAAC) and one archived FFPE sample was from VCU’s Department of Pathology [19,22].
Human tissues, patient consents, and clinical data were provided by the VCU TDAAC core
facility and the Department of Pathology with patient consents. All patient samples were de-
identified to protect patient confidentiality. Slides (10–20) were generated and reviewed by a
board certified pathologist (ED) with expertise in prostate cancer diagnosis to identify prostatic
adenocarcinoma foci versus normal glandular epithelium as well as hyperplastic glandular epi-
thelium (BPH), prostatic intraepithelial neoplasia (PIN) and stroma from one unique patient
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sample. Prostatic adenocarcinoma was graded according to the Gleason grading system [24].
Briefly, 8 μm tissue slices were placed on uncharged glass slides, dehydrated with progressively
increasing concentrations of ethanol, and stained with hematoxylin and eosin (H&E)
[19,20,25–29]. LCM was performed using an Arcturus Veritas™ laser capture microdissection
system (Life Technologies). Areas of interest (benign versus tumor plus stroma, BPH and PIN
from one FFPE sample) were individually captured onto CapSure1Macro LCM caps (Life
Technologies, Grand Island, NY).
RNA Extraction of LCM Samples
Total RNA was extracted from LCM captured material using the Arcturus1 PicoPure1 RNA
Isolation Kit (Life Technologies, Grand Island, NY) according to the manufacturer’s protocol.
Following tissue dissection, the LCM caps were incubated for 30 min at 42°C in 50 μl of extrac-
tion buffer and stored at -20°C until ready for RNA extraction. Cellular lysates from successive
slides were pooled into a single tube and mixed with 1 volume of ethanol (70%). The lysate/eth-
anol solution was loaded onto a high recovery MiraCol™ column and centrifuged at 1000 xg for
2 min followed by 16,000 xg for 30 sec. RNA was recovered in an 11 μl volume. RNA concen-
tration and quality were measured using an Agilent RNA 6000 Pico chip with the Bioanalyzer
2100 (Agilent Technologies) using the manufacturer’s instructions. All samples used for
qRT-PCR displayed RNA of good quality as assessed by its RNA Integrity Number (RIN) and
of sufficient quantity to not require a pre amplification step for subsequent PCR analysis. RNA
(40 ng) was reverse transcribed for miR analysis using the qRT-PCR conditions described
above.
Luciferase+3’-UTR Reporter Assays
The 3’-UTR of the human ErbB2 gene (from -1 to -576 downstream of the stop codon) and
referred to as pErbB2wtUTR was kindly provided by Dr. Christopher C. Benz [30]. The entire
3’UTR (-1 to -576) as well as subregions from -44 to -576 or -110 to -576 were retrieved by
PCR using the appropriate 3’-UTR primers and the pErbB2wtUTR plasmid as template and
cloned into the Xba site of the pmirGLO dual luciferase expression vector (Promega) to gen-
erate pErbB1/576, pErbB44/576 and pErbB110/576, respectively. The 3’-UTR sequence of
the wild type and deleted subclones was verified by DNA sequencing. M12 cells (200,000
cells per well in a 6 well dish plated the day before) were transfected in triplicate with 1 μg of
pmirGLO empty vector or plasmid containing the individual 3'-UTR regions from pErbB2 as
described above. Transfection was accomplished using the TransIT1-LT1 Transfection
Reagent (Mirus BIO LLC) according to manufacturer’s recommendations. A mix of reagent
(2 μl TransIT1-LT1 /ng DNA), plasmids, and serum free RPMI media were incubated for 30
min at room temperature prior to addition to cells and incubated under normal cell culture
conditions for 48 hours followed by collection and lysate preparation according to manufac-
turer’s instructions. Luciferase and renilla activity were measured in 30 μl of cell lysate using
the Dual Luciferase Assay System (Promega Corporation) and a GloMax1 20/20 lumin-
ometer (Promega Corporation). Reporter activity is expressed as the ratio of firefly to renilla
activity. Each assay was repeated three times and the standard deviation within each sample
is noted.
A miR-22 binding site within PTEN was identified by Bar et al.[31]. A top strand (56 bases
of sequence 5’-CATATTGGTGCTAGAAAAGGCAGCTAAAGGAAGTGAATCTGTATTGGGGTA
CAGGT) and bottom strand (62 bases of sequence 5’- (TCGAGTATAACCACGATCTTTTCCGT
CGATTTCCTTCACTTAGACATAACCCCATGTCCAGC 62 bases) with the centrally located
miR-22 target region (in italics) was synthesized and directionally cloned into the Sac/AccI site
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of pmirGLO (Promega). A mutant PTEN 3’-UTR sequence containing a C (red) to A mutation
which has been shown to abolish regulation by miR-22 binding was similarly synthesized and
cloned [31]. Both wild type and mutant PTEN 3’-UTR sequences were confirmed by DNA
sequencing. Transient transfections into the M12 cell line were completed as described above
except 250 ng of the various pmirGLO plasmids was found optimal for transfection.
Western Immunoblotting
Whole cell extracts were prepared as previously described [22]. Protein (30 μg) was analyzed
on a Novex1 4–12% Tris-Bis gradient polyacrylamide gel and immunoblot analysis performed
as described previously [32]. Primary antibodies used were β-actin (1:200) produced in mouse
(C4:Santa Cruz Biotechnologies Inc.) and PTEN (1:1000) produced in rabbit (D4.3:Cell Signal-
ing). After incubation in primary antibody overnight, the blot was washed as previously
described [32] and incubated first in secondary anti-mouse IgG-HRP (1:1000) produced in
goat (Santa Cruz Biotechnologies) and then with anti-rabbit IgG-HRP (1:1000) produced in
goat (Cell Signaling) for 1 hour at room temperature. After washing bands were developed
using the chemiluminescent reagents fromWestern Lightning1 (Perkin Elmer, Boston, MA).
Western blots were exposed and bands quantitated using the ODYSSEY1 Fc Imaging System
(LI-COR Biosciences, Lincoln, NE).
Cell Proliferation Assay
The proliferation of M12 versus the stable transformed cell lines, M12+miR125b and M12
+miR-22i was compared. Cells were trypsinized, washed free of trypsin with serum-contain-
ing media, and plated in triplicate (20,000 cells/well) in 9-well plates. The viable cell number
was quantitated at 0, 48, and 72 hours with a Beckman Coulter Vi-CELL-XR Automated Cell
Viability Analyzer using a trypan blue solution. The average viable cell number was plotted on
an exponential curve with the standard deviation noted. Cell growth was compared at 0, 48
and 72 hour time points using a student t-test yielding a p-value of 0.11 and 0.009,
respectively.
Migration Assay
Migration and invasion assays were performed as previously described [19,22]. Cells were
detached from the plate using 2.0 ml of CellStripper™ (CellGro1, Manassas, VA), pelleted,
washed in serum free RPMI 1640 and re-suspended at a concentration of 2.5 x 105 cells/ml. A
cell suspension (50,000 cells in 200 μl) was added to the top chamber of a 6.0 μm pore size
ThinCert™ tissue culture insert (Greiner Bio-one BVBA/SPRL, Monroe, NC). Serum contain-
ing media (O.5 ml) supplemented with 10 ng/ml of EGF was added to the lower chamber. Cells
were incubated at 37°C for 20 hours. Media was removed from both chambers and cells that
did not invade (top surface) were removed with a sterile cotton applicator. Cells on the lower
surface were fixed in 0.025% glutaraldehyde in PBS for 20 min. Following fixation, inserts were
stained with 0.1% leucocrystal violet in 10% ethanol and PBS for 30 min and washed with ster-
ile deionized water. Membranes were excised and mounted on a glass microscope slide. Cells
were counted in 10 random fields at a 200 X magnification. Data is presented as the mean sum
of migratory cells in 10 random fields ± standard error.
Invasion Assay
Invasion assays were carried out in a manner similar to the migration assays. At least 30 min
prior to extracting cells, 60 μl (diluted 1:10) of Culturex1 reduced growth factor basement
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membrane (Growth Factor Reduced) was added to the top chamber of the ThinCert™ tissue
culture insert and incubated at 37°C for gelling. The remainder of the protocol is identical to
the migration assay described above. Data is presented as the mean sum of invasive cells in 10
random fields ± standard error.
Reverse Phase Microarray (RPPA)
RPPA experiments were conducted at the George Mason University Center for Applied Prote-
omics and Molecular Medicine under the supervision of Dr. Emanuel Petricoin III [16,17]. To
minimize variation duplicate cell pellets were used for RNA extraction for miR profiling and
for proteomics [18]. For RPPA, cell pellets were harvested by scrapping, washed with PBS,
flash frozen and stored at -80°C until used. Pellets were directly lysed in a tissue extraction
buffer and spotted on a nitrocellulose coated glass slide (Grace Bio-labs, Bend OR) in a minia-
ture dilution curve (1:1, 1:2, 1:4, 1:8, and 1:16) using an Aushon 2470 arrayer (Aushon BioSys-
tems Billerica, MA) to ensure accurate quantification of each protein measured [16]. Three
successive passages for each cell line were analysed with each sample printed in triplicate along
with standard curves for internal quality control. Selected arrays were stained with Sypro Ruby
Protein Blot Stain (Molecular Probes, Eugene, OR) following manufacturing instructions to
quantify the amount of protein present in each sample. Prior to antibody staining the remain-
ing arrays were treated with Reblot Antibody Stripping solution (Chemicon, Temecula, CA)
for 15 min at room temperature, washed with PBS, and incubated for at least one hour in I-
block (Tropix, Bedford, MA). Using an automated system (Dako Cytomation, Carpinteria,
CA), arrays were first probed with a 3% hydrogen peroxide, biotin blocking system, and then
an additional serum free protein block to reduce nonspecific binding between endogenous pro-
teins and the detection system. Antibodies were validated for their use on the array by verifying
single-band Western blotting and peptide completion/ligand induction. ErbB2/3, pBAD,
pERK and MET were rabbit monoclonal antibodies, PI3K a rabbit polyclonal, all supplied by
Cell Signaling, Inc. Biotinylated anti-rabbit (Vector Laboratories, Inc. Burlingame, CA) or anti-
mouse secondary antibody (CSA; Dako Cytomation Carpinteria, CA) coupled with the Cata-
lyzed Signal Amplification System (CSA; Dako Cytomation Carpinteria, CA), a commercially
available tyramide-based avidin/biotin amplification kit, were employed to amplify the detec-
tion of the signal. Fluorescent detection was obtained using IRDye 680RD Streptavidin
(LI-COR Biosciences, Lincoln, NE) according to the manufacturer’s recommendation. Anti-
body and Sypro Ruby stained slides were scanned on a Tecan laser scanner (TECAN, Mönne-
dorf, Switzerland) using the 620 nm and 580 nm weight length channel respectively. Images
were analysed with MicroVigene Software Version 5.1.0.0 (Vigenetech, Carlisle, MA) as previ-
ously described [16]. Overall, the cellular lysate was spotted onto 111 slides and each incubated
with a unique antibody. Data was returned on a Microsoft Excel spreadsheet containing each
cell type analyzed with each antibody of interest.
Statistical Analysis of the RPPA Data
Microsoft Excel was used to perform a two-sample equal variance T-test to compare the pro-
tein expression data between the M12 and p69 cell lines. A total of 45 values was averaged for
each antibody probed protein sample. A strict probability value of p< = 0.001 was used to cor-
rect for variation among multiple samples and to identify truly significant changes. The
reported significant changes were converted into fold changes by dividing the average expres-
sion of the protein in the M12 cell line by the average expression of the protein in the compara-
tive p69 cell line.
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Results
Next Generation Sequencing of Prostate Cancer Cell Lines
The p69, M2182, and M12 cell lines represent an unique set of genetically related prostate can-
cer cell lines proposed as a progression model duplicating the molecular events that occur dur-
ing prostate tumorgenesis in vivo [13,14,15]. The M12 cell line is a highly tumorigenic/
metastatic variant derived from the parental p69 cell line with the M2182 cell line displaying an
intermediate, but non—metastatic phenotype. In contrast, other established human prostate
cell lines such as Du145 or PC3 represent cellular end points derived from secondary tumors
and thus, cannot be viewed as a progression model.
Next generation sequencing (NGS) analysis was undertaken to identify potential nucleotide
variations in genes known to be associated with cancer progression that could account for the
phenotypic differences displayed by these cell lines. Over 200,000 reads were obtained for each
subline with a mean read length of ~110 nts in length (Table 1). The Catalogue of Somatic Muta-
tions in Cancer (COSMIC) describes over two million coding sequence point mutations identi-
fied in various cancers. However, there were only three COSMIC gene mutations identified in all
sublines (STK11-COSM29005, PGFRA- COSM22413 and APC-COSM19099) (Table 2). Inter-
estingly, all of the COSMICmutations plus an additional 11 novel mutations were consistent
across all members (P69, M2182 andM12) of the prostate cancer cell progression model. There
was a single transition from a thymidine to a cytosine in the STK11 gene, which was not present
in the M12 cell line, but since this is NOT a mutation known to correlate to cancer risk, it is
unlikely that it is solely responsible for the unique properties of this subline. Thus, the NGS anal-
ysis showed that there were no previously known cancer gene mutations that could account for
the vast differences in tumorigenicity and metastasis displayed by these related cell lines.
Analysis of miR Expression in Prostate Cancer Cell Lines
To identify genes that could contribute to the different tumorigenic/metastatic properties of
these cells, a miR array screen using the miRCURY LNA ™ Universal RT microRNA PCR sys-
tem (Exiqon, Denmark) was conducted in duplicate [18,21]. Although several miRs were
found to be dysregulated, most notable was the differential expression of miR-125b and miR-
22 [18,21]. As the prostate cell lines became more tumorigenic progressing from the parental
p69 to the M2182 and ultimately the M12 cell, the level of miR-125b decreased substantially,
a 6-fold drop in expression (Fig 1). In contrast, miR-22 likely functioned as an oncomiR with
the level of miR-22 increasing 3.5-fold as the cells became more tumorigenic and ultimately
metastatic. Interestingly, in both cases the bulk increase occurred during the early phases of
tumorigenesis from P69 to M2182 with only slight additional changes in the transition from
M2182 to the M12 cells.
MiR Expression in Tumor Tissue RNA Extracted by LCM
To confirm those findings observed with prostate cancer cell lines, miR dysregulation was
assessed in human tumors obtained after radical prostatectomy. Determination of molecular
Table 1. Next generation sequencing results in prostate cancer cell line model.
Cell Line Reads Mean Length Total Bases
P69 562,713 110 61,626,082
M2182 206,177 114 23,518,988
M12 448,016 114 50,956,206
doi:10.1371/journal.pone.0142373.t001
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changes contributing to pathogenesis in the prostate is complicated by the heterogeneity of the
tissue. Frequently, tumor of varying Gleason scores are surrounded by normal glandular tissue
all embedded in stroma as noted (Fig 2). Pure cell populations can only be obtained from such
a heterogeneous tissue with techniques like LCM [19,20,25–29], which allows for the direct
Table 2. Single nucleotide variations in prostate cancer cell line model.
Gene Symbol Chromosome Position Reference Nucleotide Alternate Nucleotide Cosmic ID
PIK3CA chr3 178917005 A G —
MET chr7 116340269 C T —
NOTCH1 chr9 139390853 C T —
RET chr10 43613843 G T —
TP53 chr17 7579472 G C —
STK11* chr19 1220321 T C —
STK11 chr19 1221293 C T COSM29005
PIK3CA chr3 178927410 A G —
FGFR3 chr4 1807894 G A —
PDGFRA chr4 55141055 A G —
PDGFRA chr4 55152040 C T COSM22413
KDR chr4 55955139 A T —
APC chr5 112175240 G C COSM19099
APC chr5 112175770 G A —
CSF1R chr5 149433596 TG GA —
*Not present in M12 cell line
doi:10.1371/journal.pone.0142373.t002
Fig 1. Dysregulation of miR-125b andmiR-22 in the p69/M12 human prostate cancer cell line progressionmodel.Comparison of miR-125b (grey) and
miR-22 (black) levels in RNA extracted from p69, M2182 and M12 cell lines by SYBR based qRT-PCR as described in Materials and Methods. Fold
difference was calculated as the mean of three independent experiments analyzed in triplicate and normalized to RNU48 (ΔCT) as an internal control and
expressed relative to the parental p69 cell line using the comparative CT method [23]. ANOVA test indicates a significant difference with a P-value < 0.05.
doi:10.1371/journal.pone.0142373.g001
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visualization and collection of selected cells, yielding a pure source of RNA for downstream
analyses. For example, an adjacent region from the tissue sample illustrated in Fig 2 contained
prostatic urethra, and if it had been included, as it would have been in the analysis of a whole
tumor sample, the results could have been significantly compromised. Thus, normal glandular
epithelium or selected tumor cells captured with the exclusion of stroma or other benign ele-
ments are the best source for subsequent miR analysis. Comparing matched tumorigenic epi-
thelium to its benign counterpart, we confirmed the findings of our in vitro cell line model.
The level of miR-125b was significantly lowered (2.5-fold) in tumor cells compared to benign
epithelium where miR-22 was3.2-fold higher (Fig 3A).
In contrast with frozen tissue, dissection of FFPE samples is not time limited and provides
an ideal opportunity to more finely resolve changes that occur during tumor progression by
the collection of graded tumor RNA free from benign epithelium or stroma. In contrast, the
major disadvantage of using FFPE samples is the limited quantity of extracted RNA as a higher
quantity was consistently obtained from frozen samples (Fig 3A). For this reason, only a single
miR could be chosen for further evaluation in an interesting FFPE sample. This patient’s sam-
ple displayed a wider range of cell- and tumor-types that could be used to further document
the pattern of miR-125b activity during the tumorigenic process (Fig 3B). Benign prostatic
Fig 2. LCM is required to minimize variation due to tissue heterogeneity of human prostate tissue. This image of a frozen human prostate sample
exemplifies the heterogeneity typical of human tissues: areas of adenocarcinoma, outlined in blue, are intermixed with stroma and benign prostate glands,
labeled by arrows. LCM allows for targeted dissection of the malignant glands (scored as G3 and G4 for this particular sample) while avoiding the stroma and
other benign structures.
doi:10.1371/journal.pone.0142373.g002
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epithelium, stroma, benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia
(PIN), and tumor were separately dissected by LCM and analyzed. BPH is a common disorder
affecting nearly all men at some point in their lifetime and in general it is not thought to
increase a man’s risk of developing prostate cancer [33]. The level of miR-125b decreased in
BPH cells when compared to normal benign epithelium (Fig 3B). However, there was a great
Fig 3. Dysregulation of miR-125b andmiR-22 expression in RNA extracted from prostate tissue
samples by LCM. (A) Frozen prostate samples were dissected via LCM into benign glandular epithelial
versus tumor. Total RNA was extracted using the PicoPure RNA extraction method, as described in Materials
and Methods. qRT-PCRwas performed with specific primers against miR-125b and miR-22 using the
TaqMan1 Universal Master Mix II. CT values were normalized to RNU48 and reported as fold differences
compared to benign tissue using the ΔΔCTmethod of Livak et al. [23]. Results are the average from frozen
tissue samples (n = 4) repeated in 3 technical replicates. (B) From 10 successive slides of a single FFPE
prostate sample, miR-125b was quantitated by qRT-PCR as described in panel A for RNA extracted from
stroma, benign glandular tissue, BPH, PIN and tumor of stage G4.
doi:10.1371/journal.pone.0142373.g003
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range of miR-125b levels in BPH cells as evident by the large standard deviation. PIN is consid-
ered to be a precursor for the development of prostate carcinoma [34,35]. Many of the genetic
changes that drive prostate cancer occur early in pathogenesis and are evident in PIN cells.
Interestingly, there was a more stable 2.5-fold decrease in miR-125b expression in PIN when
compared to the benign epithelium. By the time of progression to tumor, the loss of miR-125b
was drastically reduced ( a 12-fold decrease). Thus, as seen earlier, the overall level of miR-
125b dropped as the oncogenic nature of the tissue increased even beginning as early as BPH
and certainly by the establishment of PIN with practically complete loss by the tumor stage in
this patient’s sample.
RPPAMeasurement of Protein Content in Prostate Cancer Cell Lines
Previously, gene array profiling has been used to distinguish genes that are dysregulated during
the development of disease. It was traditionally thought that mRNA expression reflected actual
protein levels. However, knowledge of post-transcriptional controls that affect mRNA transla-
tion challenges this traditional theory. It is now known that most genes are influenced by at
least one miR. Thus, mRNA expression correlates poorly with protein levels. Direct measure-
ment of protein content via a proteomic approach would be a better indicator of overall miR
regulation than gene arrays.
To better correlate changes in miR expression with protein levels, p69 and M12 cell extracts
were subjected to RPPA analysis, surveying the expression of 111 different proteins deemed
important in cancer. After verification of internal standards and normalization, several pro-
teins exhibited a significant change in expression. Of these, the most significant changes were
exhibited by ErbB2, ErbB3, PI3K, p-BAD, MET, and pERK (Table 3). Although a role for the
ErbB family of proteins has been well documented in breast cancer, a connection in prostate
cancer has only recently been proposed [36,37].
Correlation of RPPA Analysis with miR Expression
miR expression analysis confirmed a substantial loss of miR-125b in relevant prostate cell lines
and in actual tumor cells via LCM analysis. It has been proposed that the binding sites for miR-
125b are contained within the 3’-UTRs of ErbB2 and ErbB3 [30]. Thus, a correlation between
RPPA results and miR-125b expression was explored.
Analysis of ErbB2’s 3’-UTR suggested, in addition to the known miR-125b binding site (site
#1) at position 19–44 downstream of the stop codon, a second binding site (site #2) at position
70 to 96 was likely (Fig 4A). Both sites exhibited a perfect match between the seed region of
miR-125b and the corresponding target region of ErbB2 with a favorable Molecular Free
Energy (MFE) structure of -21.9 and -24.4 kcal/mol, respectively (Fig 4A). The pmirGLO plas-
mid containing ErbB2’s wild type 3’UTR (1/576) resulted in a considerable reduction (60%)
in luciferase activity compared to empty vector when transfected into the M12 cell line (Fig
4B). A similar result was detected in the breast cancer cell line SKBR3-125b [30]. Deletion of
site #1 (a proven target for miR-125b) in pErbB44/576 restored considerable activity (>50%),
but further deletion of the potential new site#2 (110/576) was required to completely restore
luciferase activity back to vector only levels.
The RPPA analysis confirmed the role of the PI3K pathway and ErbB family in prostate
cancer [38,39]. PTEN is a known cellular brake for this pathway [31]. miR-22 is known to regu-
late PTEN activity by binding to its 3’-UTR [31]. In the M12 cell line we confirmed that muta-
tion of a single C to an A within PTEN’s wild type binding site resulted in a considerable
restoration of luciferase activity matching that obtained in the initial report by Bar et al. (Fig
4C). Since PTEN levels were not analyzed in the original RPPA, western blots confirmed that
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PTEN expression was significantly reduced (2.7-fold) in M12 cells compared to parental p69
cells (Fig 4D and 4E) (entire gel included as S1 Fig).
Restoration of miR-125b or Decrease of miR-22 Affected the Migratory
and Invasive Behavior of the M12 Cancer Cell Line
To further explore the role of miR-125b and miR-22 in prostate tumorigenesis, M12 stable cell
lines were constructed that either increased expression of miR-125b (M12+miR125b), or
expressed a proven miR-22 inhibitor, (M12+miR-22i). An analysis of an important negative
control of the M12 stable cell line expressing a scrambled RNA sequence of similar length to
miR125b (M12+scrambled RNA) was included and described previously as M12+NTC [22]. In
the case of miR-125b restoration, qRT-PCR confirmed a 3.5-fold increase in miR-125b levels
in M2+miR-125b cells versus parental M12s or the M12+scrambled RNA control.
The proliferation rate of M12+miR-22i versus the parental M12 cells was compared (Fig
5A). At 24 hours cell growth was equivalent yielding a p value of 0.11, but by 72 hours the pro-
liferation rate of the modified cell line started to slow down (p value = .009) probably due to
the decrease in functional miR-22 contributing to an increased level of the cellular brake PTEN
(see Fig 4D and 4E). However, no differences in growth rate were detected for M12s compared
to the stable M12+miR-125b cell line (negative data not shown).
Since no significant proliferative differences were noted for altering miR-125b or miR-22
expression at 20 hours, the effect of these modifications on cell migration and invasion was
determined. Restoration of miR-125b resulted in a substantial decrease in migratory ability
(3.7-fold) for M12+miR125b in Transwell chamber assays versus a similar decrease when the
action of miR-22 is inhibited (Fig 5). Similar results were obtained for measurement of invasive
ability. A scrambled RNA control either showed a slight increase (25%) in migratory behavior
or no measurable effect on invasion. Western blots confirmed that upon inhibition of miR-22,
PTEN activity was increased 7-fold (Fig 4D and 4E).
Discussion
Previous network analyses of oncogenic cell lines suggested that miRs preferentially target pro-
tein nodes that regulate key processes implicated in cancer progression [11,12]. Our work sub-
stantiates this hypothesis by comparing miR array results with proteomics. To our knowledge
this is one of the first studies aimed at directly correlating miR expression levels to protein
quantity rather than transcript levels revealed by the usual gene arrays (Table 3). Since miR
binding doesn’t necessarily result in the degradation of all target mRNAs, studies that attempt
to correlate mRNA levels to miR arrays to deduce targets for miR binding may not be
Table 3. RPPA analysis shows increased protein expression from the PI3K/RAS pathways in M12 ver-
sus p69 Cell Lines.
Protein Fold change*
ErbB2 1.8
ErbB3 2.0
PI3K 1.4
p-BAD 1.7
MET 1.3
pERK 4.0
*All p values for these comparisons are < 0.001
doi:10.1371/journal.pone.0142373.t003
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consistent. The more relevant comparison is miR array data compared to protein product anal-
ysis, as western blots and luciferase+3’-UTR assays have been instrumental in validating miR:
mRNA targeting. Moreover, differences in the tumorigenic/metastatic properties of these
related cell lines could NOT be explained by the acquisition of nucleotide mutations within
Fig 4. Validation of miR-125b andmiR-22 binding to the 3'-UTR of ErbB2 and PTEN respectively. (A) Identification of two miR-125b binding sites within
the 3’-UTR of ErbB2. Site 1 (position -19 to -44) downstream of the stop codon is proven by Scott et al [30]. Site 2 (position -70 to -96) is proposed here by an
analysis with RNAhybrid [56]. Both sites display notable binding between ErbB2’s 3’-UTR (red) and miR-125b (green) with favorable MFEs. (B) The M12 cell
line was transfected with a dual luciferase reporter construct containing various portions of ErbB2’s 3’-UTR as noted. Firefly luciferase expression is
normalized to renilla luciferase activity. Results are the mean of 3 independent experiments each performed in triplicate. ANOVA test indicates a significant
difference with a P-value < 0.05. (C) The effect of miR-22 binding on the wild type and mutant PTEN 3’-UTR target binding site was assessed on firefly versus
renilla luciferase activity as described in panel B via transfection into the M12 cell line. Mutation of a single base (C to A) within the target to miR-22’s seed
region [31] resulted in increased firefly luciferase activity. Results are the average of 3 experiments repeated in triplicate. (D) A representative western blot of
whole cell extracts (30 μg) fromM12, M12+miR-22i and p69 cells. Proteins were separated on a 4–12% Tris-Bis gel and incubated with a PTEN antibody. β-
actin was used as a loading control. The position of migration of relevant protein size markers are noted. (E)Quantitation of western blot shown in panel D
with PTEN levels normalized to β-actin.
doi:10.1371/journal.pone.0142373.g004
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Fig 5. Restoration of miR-125b or inhibition of miR-22 impairs in vitromigratory and invasive potential of M12 cells but initially has little effect on
cell proliferation. (A) A representative growth curve of M12 versus M12+miR-22inhibitor cells is shown. Cells (20,000) were plated in triplicate and viable
cells counted at 0, 48, and 72 hours in a Beckman Coulter Vi-CELL automated cell viability analyzer using trypan blue exclusion (cell viability >94%). The
average viable cell number was plotted on an exponential curve with the standard deviation noted. Analysis of cell growth at the 48 and 72 hour time points
using a student t-test yielded a p-value of 0.11 and 0.009, respectively (B) Cells (50,000) were plated in triplicate in serum free media in the top chamber of a
ThinCert™ tissue culture insert and processed as described in Materials and Methods. Panel A confirmed no significant difference in growth potential at 20
hours at which time the number of migrated cells was counted in 10 random fields and the total number of migratory cells estimated by summing up each of
the individual fields. The average mean sum of each well is presented, along with the standard error. The invasion assay used the same experimental set up
with the additional step of coating the membrane with Culturex1 growth factor reduced basement membrane (60 μl) prior to cell addition. Results are shown
for parental M12 cells or M12 cells stably transformed with a scrambled RNA sequence as a negative control (M12+scrambled RNA), a miR-22 inhibitor (M12
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known cancer genes (Table 2). This result strengthens the likelihood of differences in miR
expression as major contributors to tumor progression.
This three pronged approach of network analysis supported by miR arrays and proteomics
has suggested two miRs as important regulators of prostate tumor progression. The importance
of miR-125b as a tumor suppressor and miR-22 as an oncomiR was initially suggested by
qRT-PCR analysis of the p69, M2182 and M12 cell lines [18]. The appropriateness of this
model system for accurately reflecting tumorigenesis was supported by LCM analysis of actual
human prostate tumor samples. Moreover, luciferase+3’-UTR constructs validated a direct
interaction between miR-125b binding to ErbB2 with the identification of a second binding
site (Fig 4B). Confirmation of site#1 agrees with previously published results in SKBR3 cells,
but our study suggests that complete repression by miR-125b requires at least two binding sites
within ErbB2’s 3’-UTR. Similarly, miR-22 was shown to directly bind to PTEN (Fig 4C). Resto-
ration of miR-125b or inhibition of miR-22 expression resulted in a substantial decrease in the
migratory and invasive abilities of the M12 cell line (Fig 5), which could not be accounted for
by strictly modifying growth rate.
Altogether these results suggest an interesting cooperation between miR-125b and miR-22
in regulating key signal transduction pathways known to be dysregulated in prostate cancer
progression (Fig 6). In this case, a decrease in miR-125b would permit increased expression of
ErbB2/3 resulting in enhanced levels of PI3K and BAD as one signal transduction pathway
increased in our proteomic data (Table 3) and in prostate tumorigenesis [39]. Concurrently,
the overexpression of miR-125a/b was found to reduce ErbB2/3 at both the transcript and pro-
tein level in the human breast cancer cell line SKBR3 thereby reducing AKT signaling [30]. In
addition, a noted increase in the amount of MET protein, another known target of miR-125b
expression, would lead to an increase in RAS signaling thru the pMEK/pERK pathway, also
shown to be increased in prostate cancer and supported by our proteomic data (Table 3). Con-
versely, the overexpression of miR-22 would lower PTEN levels, the cellular brake known to
fine tune the PI3K/AKT pathway [40]. Reduced expression of PTEN would further result in
enhancement of the PI3K signaling pathway [40]. In HEK293T cells, miR-22 gene expression
has been shown to be transcriptionally upregulated by the AKT pathway in a feed forward
loop, which would further decrease PTEN levels [31]. Thus, the dual dysregulation of these two
miRs could easily disrupt the normal homeostasis of cellular expression contributing to an
enhanced tumorigenic/metastatic phenotype. Although the importance of the PI3K/AKT and
MEK/ERK pathways as known modulators of prostate cancer progression is documented [38],
how the expression of these pathways could be modulated in prostate cancer has not been
established. Our studies suggest a mechanism by which these signal transduction pathways are
enhanced in prostate tumorigenesis due to the loss of miR-125b and overexpression of miR-22.
miR-125b has been reported to be dysregulated in a variety of cancers, either acting as an
oncomiR being up-regulated in diffuse-type gastric cancer [41], colon [42], pancreatic [43],
and urothelial carcinomas [44] or as a tumor suppressor being down regulated in drug-resis-
tant ovarian cancer [45], breast [46], head and neck squamous cell carcinoma [47] and in liver
cancer [48]. In breast [46] and ovarian cancer [49], promoter methylation has been shown to
account for decreased miR-125b expression.
Conflicting results for miR-125b expression have been reported for prostate cancer cell
lines. Shi et al found miR-125b to be increased in androgen stimulated prostate cell lines such
as LNCaP or in the PC3 prostate cell line where increased miR-125b expression promoted the
+miR-22 inhibitor) or restored miR-125b (M12+miR-125b). Data is the mean of 3 independent experiments, each performed in triplicate. ANOVA test
indicates a significant difference with a P-value < 0.05.
doi:10.1371/journal.pone.0142373.g005
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growth of prostate cancer xenografts by targeting pro-apoptotic genes [50,51]. Conversely,
miR-125b was reported to be downregulated in prostate carcinomas comparing these same cell
lines, xenografts thereof and in clinical prostate tissue samples [52], and in miR array screens
of prostate tumor tissue matched to normal tissue as confirmed by qRT-PCR assays [53,54]. It
Fig 6. Model for dual regulation by miR-125b andmiR-22.RPPA data shows increases in ErbB3, ErbB2, MET, PI3K, pBAD and pERK protein expression
in M12 cells relative to the parental p69 cell lines (Table 3: green targets). Western blot (Fig 4D) confirms a decrease in PTEN expression (red). These
proteins figure prominently in signal transduction pathways that are targeted by miR-125b and miR-22. Intermediates in yellow (AKT, RAS and pMEK) were
not included in the proteome analysis. miR-125b directly targets ErbB2, ErbB3 and MET and miR-22 targets PTEN [30,31]. We propose that the loss of tumor
suppressor miR-125b in the M12 cell line would result in enhanced signaling via the PI3K/AKT pathway and the RAS/pMEK pathway as regulated by MET.
Conversely, miR-22 targets PTEN, the loss of which by increased expression of miR-22 further exacerbates PI3K signaling. In this scenario the dysregulation
of these two miRs could contribute to the highly tumorigenic/metastatic phenotype displayed by the M12 cells compared to the parental p69 cell line and
subsequently contribute to prostate tumorigenesis.
doi:10.1371/journal.pone.0142373.g006
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is not clear why the discrepancy in results with these prostate cell lines, but it was suggested
this may be affected by androgen withdrawal leading to an increase in p53 expression [51].
Due to the heterogeneity of whole prostate tumors, it is likely that differences in miR-125b
expression patterns among individual whole tumors are not surprising [19,26–29,55,56].
When LCM retrieval of separate tumor from normal tissue is employed, miR-125b shows a
definite decrease early in tumorigenesis, which supports miR-125b’s putative role as a tumor
suppressor. Considerable miR-125b expression in stroma tissue (Fig 3B) could contribute to
the variable results obtained from whole tumor analysis dependent upon the amount of con-
tamination from stroma and other non-tumor cell types. We characteristically detected patches
of tumor of different grades G3, G4, or G5 (Fig 2) [19], BPH or PIN intermixed in the same
tumor sample (Fig 3B) as well as patches of lymphocytes or prostatic urethra. There is little
doubt that solid tumors are heterogeneous further contributing to conflicting results. There-
fore, more targeted methods like LCM, which can retrieve single cell-types, leads to improved
analysis. In support of our findings, a similar LCM study found miR-125 to be down-regulated
2.2-fold in pooled FFPE prostate cancer samples compared to their normal counterparts (5
Caucasians and 5 African) [35]. However, since these results were reported for only a pooled
sample, it is impossible to monitor individual sample variability or compare expression across
various stages of prostate cancer as reported here, i.e., BPH versus PIN. Additional LCM stud-
ies are required to further address this hypothesis.
Conclusion
In conclusion, our approach has uncovered the loss of miR-125b acting as a tumor suppressor
and the overexpression of the oncomiR miR-22 in promoting prostate tumor progression. As
more studies strive to undercover multiple targets for individual miRs, an additional level of
complexity may come from the combinatorial effect of miRs, which together exert a greater
effect on cancer progression than any single miR acting alone. Given that each miR is proposed
to target hundreds of mRNAs, a combination of miRs would certainly have an even greater
effect than any single miR. In this regard, it will be interesting to note what other miRs act in
concert to further regulate tumorigenesis and metastasis.
Supporting Information
S1 Fig. Entire western blot of whole cell extracts (30 μg) fromM12, M12+miR-22i and p69
cells as shown in Fig 4D. A blank and duplicate p69 lane shown here were deleted from Fig
4D.
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